The Conversation reports cataract surgery is safe and common, with over 90% achieving 20/20 vision, but patients need to ...

Successful explantation of a corneal microlens for presbyopia and implantation of a trifocal IOL in a patient who developed ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Primary IOL implantation in pediatric open globe injuries with active inflammation showed inferior visual outcomes compared ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Celebrating 75 years of intraocular lens advancements that have improved care for millions of cataract patients. On November 29, 1949, Sir Harold Ridley performed a surgical procedure to replace a ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

The new approvals are the latest in Johnson & Johnson’s IOLs; the Company claims the new TECNIS Eyhance IOL can slightly extend the depth of focus and deliver better image contrast. The Food and Drug ...

Purpose This study was carried out to evaluate the postoperative visual results and complications following epilenticular intraocular lens implantation in paediatric traumatic cataracts. Materials and ...